Stocks & Investing
Stocks and Investing
Stocks and Investing
Thu, July 6, 2023
[ Thu, Jul 06th 2023
] - WOPRAI
[ Thu, Jul 06th 2023
] - WOPRAI
[ Thu, Jul 06th 2023
] - WOPRAI
[ Thu, Jul 06th 2023
] - WOPRAI
[ Thu, Jul 06th 2023
] - WOPRAI
[ Thu, Jul 06th 2023
] - WOPRAI
[ Thu, Jul 06th 2023
] - WOPRAI
[ Thu, Jul 06th 2023
] - WOPRAI
[ Thu, Jul 06th 2023
] - WOPRAI
[ Thu, Jul 06th 2023
] - WOPRAI
[ Thu, Jul 06th 2023
] - WOPRAI
[ Thu, Jul 06th 2023
] - WOPRAI
[ Thu, Jul 06th 2023
] - WOPRAI
[ Thu, Jul 06th 2023
] - WOPRAI
[ Thu, Jul 06th 2023
] - WOPRAI
[ Thu, Jul 06th 2023
] - WOPRAI
[ Thu, Jul 06th 2023
] - WOPRAI
[ Thu, Jul 06th 2023
] - WOPRAI
[ Thu, Jul 06th 2023
] - WOPRAI
[ Thu, Jul 06th 2023
] - WOPRAI
[ Thu, Jul 06th 2023
] - WOPRAI
[ Thu, Jul 06th 2023
] - WOPRAI
[ Thu, Jul 06th 2023
] - WOPRAI
[ Thu, Jul 06th 2023
] - WOPRAI
[ Thu, Jul 06th 2023
] - WOPRAI
[ Thu, Jul 06th 2023
] - WOPRAI
[ Thu, Jul 06th 2023
] - WOPRAI
[ Thu, Jul 06th 2023
] - WOPRAI
[ Thu, Jul 06th 2023
] - WOPRAI
Ashwani Verma Upgraded (TEVA) to Hold and Increased Target to $8 on, Jul 6th, 2023
Ashwani Verma of UBS, Upgraded "Teva Pharmaceutical Industries Limited" (TEVA) to Hold and Increased Target from $7 to $8 on, Jul 6th, 2023.
Ashwani has made no other calls on TEVA in the last 4 months.
There are 3 other peers that have a rating on TEVA. Out of the 3 peers that are also analyzing TEVA, 1 agrees with Ashwani's Rating of Hold. Following is the relevant analyst calls for the last 4 months
- Thibault Boutherin of "Morgan Stanley" Initiated at Hold and Held Target at $10 on, Thursday, May 25th, 2023
These are the ratings of the 2 analyists that currently disagree with Ashwani
- Umer Raffat of "Evercore ISI Group" Upgraded from Hold to Buy on, Thursday, May 18th, 2023
- Jason Gerberry of "B of A Securities" Maintained at Strong Buy with Decreased Target to $11 on, Thursday, May 11th, 2023
